B+
Bull case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
KYTX
Kyverna TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Company-reported one-year SPS durability and longer-term gMG responses support the miv-cel thesis if the full dataset, BLA completion and Phase 3 execution remain favorable. [#8-K-2026-09-24] Kyverna release
Posture
Constructive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bullish as of 2026-10-27.
What can break
BLA timing, review outcome, manufacturing readiness and any 2027 launch remain uncertain. [#SEC-8K-2026-08-11]
Momentum
10
Value
41
Sentiment
86
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $6.80 · Bull $11.00 · Bear $3.30Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $30.40
Why
Momentum10 · Δ7d +0.9
Value41 · Δ7d -0.1
Sentiment86 · Δ7d +11.1
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-10-27.
- • Sentiment remains the lead driver in the composite, 7D delta +11.1.
Contradictions & invalidation
- • BLA timing, review outcome, manufacturing readiness and any 2027 launch remain uncertain. [#SEC-8K-2026-08-11]
- • R&D spending and potential financing or loan draws could pressure shareholders despite management's projected runway into 2028. [#PR-EARNINGS-2026-08-11]
- • Small, open-label cohorts leave substantial uncertainty about reproducibility, FDA review and commercial uptake.
Catalyst clock
2026-10-23
Full one-year SPS dataset at MS Toronto
Lead driver: Sentiment · See AI snapshot
Momentum
10
8% active weight
Current posture
7d trendImproving
Δ7d
+0.9
Δ21d
-1.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
86
45% active weight
Current posture
7d trendImproving
Δ7d
+11.1
Δ21d
+12.4
Why this grade
Composite grade B. Momentum 10.3 / Value 40.6 / Sentiment 86.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$6.80
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.30
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$348.18M
Beta
-
Shares Out
61.84M
P/E (TTM) · Derived
-1.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.82
Rev YoY
-100.0%
EPS YoY
-35.4%
Gross Margin
-474.1%
Op Margin
-
Net Debt
-$250.22M
Current Ratio
9.06
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data